AstraZeneca’s Baxfendy is the first FDA-approved drug in a new class of medicines called aldosterone synthase inhibitors. The new mechanism of action is important for patients and for AstraZeneca, which has been looking for new drugs with blockbuster potential as its top cardiometabolic medicine faces patent expiration.
The post FDA Approves AstraZeneca Drug With New Approach to Lowering High Blood Pressure appeared first on MedCity News.
